CRISPR-Cas9 is a valuable new tool for high-throughput screening. Screens can be designed to generate gene knockouts, repress genes, or activate them. Libraries of guide RNAs targeting tens of thousands of sites across the genome are introduced into cells to tease apart the functions of different genes and regions of DNA that regulate gene expression. We are collaborating with basic researchers and biotechnology companies to perform genome-wide CRISPR screens in a variety of cell types to identify genes involved in many disease pathways. We will then test candidate genes as targets for clinical drug development. CRISPR screens let us explore a wide range of disease targets, including immunological conditions like arthritis, oncological diseases such as leukemia, and metabolic disorders like diabetes, as well as cardiovascular and infectious diseases.
Read more about utilizing our high-throughput CRISPR screening facility here.
A Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic Dissection of the Unfolded Protein Response.
Adamson B, Norman TM, Jost M, Cho MY, Nuñez JK, Chen Y, Villalta JE, Gilbert LA, Horlbeck MA, Hein MY, Pak RA, Gray AN, Gross CA, Dixit A, Parnas O, Regev A, and Weissman JS. Cell (2016).
Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation.
Horlbeck MA, Gilbert LA, Villalta JE, Adamson B, Pak RA, Chen Y, Fields AP, Park CY, Corn JE, Kampmann M, and Weissman JS. eLife (2016).